XCUR
EXICURE, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.03
−8.04%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.30
From 52W high−85.87%
Volume68788.00
Market cap$6.74M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.30
From 52W high
−85.87%
Volume
68788.00
Market cap
$6.74M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
P/E (TTM)
—
RSI (14)
43.6
MomentumView details →
1D Return
−8.04%
YTD Return
−79.52%
SummaryUpdated Jun 1, 2026
Exicure, Inc. (NASDAQ:XCUR) is a biotechnology company founded in 2011 and headquartered in Chicago, Illinois. The company went public in May 2018 and focuses on developing innovative therapies for neurological disorders and hair loss using its proprietary spherical nucleic acid (SNA) technology platform. Exicure operates as a clinical-stage biopharmaceutical company with strategic partnerships including collaborations with major pharmaceutical companies AbbVie and Ipsen to advance its novel therapeutic candidates.
Similar companies
Latest newsMore news →
Nasdaq granted Exicure, Inc. an extension through December 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(b)(1) regarding stockholders' equity.33d agoExicure announced it will issue 172,058 shares of common stock to GPCR Therapeutics in August 2026 to settle a $1.0 million clinical milestone payment obligation under their License and Collaboration Agreement.77d ago